Mir Mushtaq Ahmad, Altuhami Somaya Ahmed, Mondal Sukanta, Bashir Nasreena, Dera Ayed A, Alfhili Mohammad A
Department of Clinical Laboratory Sciences, College of Applied Medical Sciences, King Khalid University, Abha 61421, Saudi Arabia.
Department of Biological Sciences, Birla Institute of Technology and Science, Pilani, K.K, Birla Goa Campus, Zuarinagar 403726, Goa, India.
Antibiotics (Basel). 2023 Mar 14;12(3):576. doi: 10.3390/antibiotics12030576.
Bacterial infections constantly have a large impact on public health, because of increased rates of resistance and reduced frequency of development of novel antibiotics. The utility of conventional antibiotics for treating bacterial infections has become increasingly challenging. The aim of the study was to assess the antibacterial effect of β-Lapachone (β-Lap), a novel synthetic compound.
The antibacterial activity of the β-Lap compound was examined against laboratory strains by agar well diffusion method and broth dilution assay. Growth kinetics in presence of β-Lap on , , and (ATCC 27853) were assessed by microplate alamarBlue assay. Crystal violet blue assay was used for biofilm inhibition and biofilm eradication. catalase (KatA) complexed with β-Lap was modeled using molecular docking approach.
β-Lap exhibited potent antimicrobial activity against laboratory strains of bacteria with MIC of 0.2 mM for and , and 0.04 mM for and ATCC 27853. The inhibition of catalase enzyme was found to be the cause for its antibacterial activity. Bioinformatics analysis suggests that β-Lap can inhibit KatA activity by interacting with catalase proximal active site and heme binding site. The activity of some commercial antibiotics was enhanced in association with β-Lap. In addition, β-Lap inhibited the biofilm formation and eradicated the already formed and ultra-mature biofilms of aforesaid bacterial strains.
These observations indicated that β-Lap could be a promising antibacterial agent for the treatment and prevention of infectious diseases.
由于耐药率上升以及新型抗生素研发频率降低,细菌感染持续对公共卫生造成重大影响。传统抗生素治疗细菌感染的效用已变得越来越具有挑战性。本研究的目的是评估一种新型合成化合物β-拉帕醌(β-Lap)的抗菌效果。
采用琼脂孔扩散法和肉汤稀释法检测β-Lap化合物对实验室菌株的抗菌活性。通过微孔板alamarBlue检测法评估在存在β-Lap的情况下,金黄色葡萄球菌、大肠杆菌和肺炎克雷伯菌(ATCC 27853)的生长动力学。采用结晶紫法进行生物膜抑制和生物膜根除实验。使用分子对接方法对与β-Lap复合的过氧化氢酶(KatA)进行建模。
β-Lap对实验室细菌菌株表现出强大的抗菌活性,对金黄色葡萄球菌和大肠杆菌的MIC为0.2 mM,对肺炎克雷伯菌和肺炎克雷伯菌ATCC 27853的MIC为0.04 mM。发现过氧化氢酶的抑制是其抗菌活性的原因。生物信息学分析表明,β-Lap可通过与过氧化氢酶近端活性位点和血红素结合位点相互作用来抑制KatA活性。一些商业抗生素与β-Lap联合使用时活性增强。此外,β-Lap抑制了上述细菌菌株的生物膜形成,并根除了已形成的和超成熟的生物膜。
这些观察结果表明,β-Lap可能是一种用于治疗和预防传染病的有前景的抗菌剂。